TB–500 5mg

TB-500 is a synthetic peptide modeled after thymosin-beta 4, a naturally occurring compound found in most cells of humans and animals. As a research chemical, TB-500 has been studied in vitro, in animal models, and limited human trials. These studies suggest its potential in promoting wound healing, muscle repair, connective tissue strength, and endothelial health.

Historical Context
Thymosin-beta 4 was first identified in 1981 when it was isolated from a bovine thymus gland sample. In the early 2010s, TB-500, developed for veterinary applications, gained notoriety for its rumored use in competitive horse racing. Horses administered TB-500 reportedly gained a significant competitive edge, prompting the development of detection methods and its subsequent ban in horse racing and other sports governed by the World Anti-Doping Agency (WADA).

Despite its prohibition in competitive sports, research into TB-500 continues, particularly in areas such as anti-aging, inflammation, cardiovascular health, and tissue repair.

What Does TB-500 Do?

TB-500 is a synthetic analog of thymosin-beta 4, a 42-amino-acid peptide integral to cellular repair and regeneration. Its chemical structure (C212H350N56O78S) and low molecular weight facilitate its actions, primarily through actin sequestration. Actin plays a critical role in cellular architecture and mobility, and thymosin-beta 4 regulates its activity at injury sites, triggering a cascade of regenerative processes.

This peptide also signals stem and progenitor cells to migrate to damaged areas and differentiate into specialized cell types, such as muscle, vascular, or connective tissue cells, aiding tissue repair and regeneration.

Potential Benefits of TB-500

1. Muscle Repair and Regeneration

• Skeletal Muscle: A 6-month study on dystrophin-deficient mice showed improved muscle fiber regeneration with thymosin-beta 4 administration.
• Cardiac Muscle: Research indicates potential benefits for heart repair post-injury through multiple protective mechanisms.

2. Connective Tissue Healing
   Thymosin-beta 4’s impact on collagen structure suggests significant potential for healing connective tissues like tendons, joints, and skin. Animal studies demonstrate that treated wounds exhibited reduced scarring, narrower widths, and more organized collagen fibers compared to untreated controls.
3. Vascular and Endothelial Function
   Thymosin-beta 4 has shown promise in promoting neovascularization (growth of new blood vessels) and improving endothelial cell differentiation, critical for vascular health and blood flow regulation.
4. Other Effects

• Metabolic Health: Animal studies link thymosin-beta 4 to improved glucose control, enhanced insulin sensitivity, and lower triglyceride levels.
• Hair Growth: Research on mice indicates its potential as a follicle stimulator, suggesting promise for hair loss treatments.

Human Trials

While most studies remain pre-clinical, some human trials have explored TB-500’s effects:

• Wound Healing: A study on venous ulcers found that 0.03% thymosin-beta 4 increased healing rates, with 25% of patients achieving complete healing in three months.
• Dry Eye Treatment: Eye drops containing thymosin-beta 4 reduced eye discomfort by 35% and improved tear production by 59% in participants after 56 days of treatment.
• Cardiac Health and Safety: Early studies in healthy adults and exploratory trials in cardiac function suggest minimal toxicity and promising therapeutic potential.

Side Effects

Research indicates that TB-500 is well-tolerated at prudent doses. A 2010 randomized controlled trial assessed doses of thymosin-beta 4 (42–1,260 mg) in 40 healthy adults, revealing minimal toxicity and only mild to moderate adverse events.

Important Note: TB-500 should only be used in controlled research settings under the supervision of qualified researchers. Self-administration for experimental or recreational purposes is strongly discouraged.

Conclusion

TB-500, as a synthetic analog of thymosin-beta 4, holds promise for a range of applications in regenerative medicine, tissue repair, and vascular health. While pre-clinical and early human trials suggest significant potential, more extensive research is required to confirm its efficacy and safety in clinical settings.

For researchers interested in exploring TB-500, consult our guide for detailed insights on its properties, benefits, and applications.

References

1. 1. Reti R, Kwon E, Qiu P, Wheater M, Sosne G. Thymosin beta4 is cytoprotective in human gingival fibroblasts. European journal of oral sciences. 2008; 116(5):424-30. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/18821984.
   2. Elitsur Y, Mutchnick MG, Sakr WA, Luk GD. Thymosin alpha 1 and thymosin beta 4 modulate human colonic lamina propria lymphocyte function. Immunopharmacology. ; 20(2):89-96. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/2266003.
   3. Sosne G, Chan CC, Thai K, et al. Thymosin beta 4 promotes corneal wound healing and modulates inflammatory mediators in vivo. Exp Eye Res. 2002;74:293–9. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/11950239.
   4. Bubb MR. Thymosin beta 4 interactions. Vitamins and hormones. 2003; 66:297-316. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/12852258.
   5. Li J, Zhang Y, Liu Y. A thymosin beta-4 is involved in production of hemocytes and immune defense of Hong Kong oyster, Crassostreahongkongensis. Developmental and comparative immunology. 2016; 57:1-9. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/26695126.
   6. Lee HR, Yoon SY, Kang HB. Thymosin beta 4 enhances NK cell cytotoxicity mediated by ICAM-1. Immunology letters. 2009; 123(1):72-6. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/19369144.
   7. Lee SJ, So IS, Park SY, Kim IS. Thymosin beta4 is involved in stabilin-2-mediated apoptotic cell engulfment. FEBS letters. 2008; 582(15):2161-6. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/18519035.
   8. Abiko T, Sekino H. Synthesis of a thymosin beta 4-like peptide, deacetyl-thymosin beta Xen4, and its restorative effect on depressed lymphocyte blastogenic response to phytohemagglutinin (PHA) in uremic patients. Chemical & pharmaceutical bulletin. 1989; 37(9):2467-71. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/2605693.
   9. Low TL, Thurman GB, Chincarini C. Current status of thymosin research: evidence for the existence of a family of thymic factors that control T-cell maturation. Annals of the New York Academy of Sciences. 1979; 332:33-48. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/394636.
   10. Carion, T. W., Ebrahim, A. S., Alluri, S., Ebrahim, T., Parker, T., Burns, J., Sosne, G., & Berger, E. A. (2020). Antimicrobial Effects of Thymosin Beta-4 and Ciprofloxacin Adjunctive Therapy in Pseudomonas aeruginosa Induced Keratitis. International journal of molecular sciences, 21(18), 6840. https://doi.org/10.3390/ijms21186840.
   11. Shrivastava S, Srivastava D, Olson EN, DiMaio JM, Bock-Marquette I. Thymosin beta4 and cardiac repair. Annals of the New York Academy of Sciences. 2010; 1194:87-96. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/20536454.
   12. Zhu J, Song J, Yu L. Safety and efficacy of autologous thymosin β4 pre-treated endothelial progenitor cell transplantation in patients with acute ST segment elevation myocardial infarction: A pilot study. Cytotherapy. 2016; 18(8):1037-42. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/27288307.
   13. Crockford D. Development of thymosin beta4 for treatment of patients with ischemic heart disease. Annals of the New York Academy of Sciences. 2007; 1112:385-95. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/17947592.
   14. Kumar S, Gupta S. Thymosin beta 4 prevents oxidative stress by targeting antioxidant and anti-apoptotic genes in cardiac fibroblasts. PloS one. 2011; 6(10):e26912. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/22046407.
   15. Evans MA, Smart N, Dubé KN, et al. Thymosin β4-sulfoxide attenuates inflammatory cell infiltration and promotes cardiac wound healing. Nature communications. 2013;4:2081. doi:10.1038/ncomms3081. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/22046407.
   16. Postrach J, Schmidt M, Thormann M. Adeno-associated viral vector 2.9 thymosin ß4 application attenuates rejection after heart transplantation: results of a preclinical study in the pig. Transplantation. 2014; 98(8):835-43. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/25321165.
   17. Bock-Marquette, I., Saxena, A., White, M. D., Dimaio, J. M., & Srivastava, D. (2004). Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature, 432(7016), 466–472. https://doi.org/10.1038/nature03000.
   18. Kim J, Jung Y. Potential Role of Thymosin Beta 4 in Liver Fibrosis. Haybaeck J, ed. International Journal of Molecular Sciences. 2015;16(5):10624-10635. doi:10.3390/ijms160510624. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4463665/.
   19. Jiang Y, Han T, Zhang Z-G, et al. Potential role of thymosin beta 4 in the treatment of nonalcoholic fatty liver disease. Chronic Diseases and Translational Medicine. 2017;3(3):165-168. doi:10.1016/j.cdtm.2017.06.003. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5643779/.
   20. Schirmacher P., Geerts A., Pietrangelo A., Dienes H.P., Rogler C.E. Hepatocyte growth factor/hepatopoietin a is expressed in fat-storing cells from rat liver but not myofibroblast-like cells derived from fat-storing cells. Hepatology. 1992;15:5–11. doi: 10.1002/hep.1840150103. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/1530788.
   21. Philp D, Kleinman HK. Animal studies with thymosin beta, a multifunctional tissue repair and regeneration peptide. Annals of the New York Academy of Sciences. 2010; 1194:81-6. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/20536453.
   22. Liang J., Cai W.J., Han T., Jing L., Ma Z., Gao Y. The expression of thymosin β4 in chronic hepatitis B combined nonalcoholic fatty liver disease. Medicine (Baltimore) 2016;95:e5763. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/28033294.
   23. Mann J., Oakley F., Akiboye F., Elsharkawy A., Thorne A.W., Mann D.A. Regulation of myofibroblasttransdifferentiation by DNA methylation and mecp2: Implications for wound healing and fibrogenesis. Cell Death Differ. 2007;14:275–285. doi: 10.1038/sj.cdd.4401979. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/16763620.
   24. Philp D, Goldstein AL, Kleinman HK. Thymosin beta4 promotes angiogenesis, wound healing, and hair follicle development. Mechanisms of ageing and development. 2004; 125(2):113-5. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/15037013.
   25. Malinda KM, Sidhu GS, Mani H. Thymosin beta4 accelerates wound healing. The Journal of investigative dermatology. 1999; 113(3):364-8. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/10469335.